I was thinking about how you had said there was a good likelihood that the sales would not be in the U.S. I missed that salient point. With the enormous China/U.S. tensions, it would hurt virtually any company importing from China, but particularly a company essentially making their very first sales from China into the U.S. would appear to have almost no shot. A “China Virus” climate is no climate to be expecting “recurrent, volume orders” into the U.S.
As for Leaderbiomed, and to clarify my misstatement, my point was not really that they would be the “end user” (always possible, I guess), but LQMT has never had a sales channel (let alone any sales of consequence) into Europe and Leader appears to have an established presence there, along with the connection to Lugee Li. An established presence with an exiting sales distribution channel would be really beneficial to a small company just trying to enter a market with a new product with new materials. If it’s Arthrex, I did see that they had a Munich location in Europe, but I was surprised to see they only have that one location in all of a Europe.
Thanks again for all your information. And I haven’t forgotten what you planned on donating a significant chunk of potential profits to. I hope others follow suit. I know I will. It’s a more than noble cause and affects way too many.
On to November, good luck.
News 
Market Data 
Discover 
